Effect of gedunin on glioblastoma proliferation and invasiveness: in vitro and in vivo approaches
Authors:
- Thadeu Estevam Moreira Maramaldo CostaTCThadeu Estevam Moreira Maramaldo Costa
- Tatiana Almeida PáduaTPTatiana Almeida Pádua
- Jonathas Xavier PereiraJPJonathas Xavier Pereira
- Vinicius Gonçalves RodriguesVRVinicius Gonçalves Rodrigues
- Leonardo Noboru SeitoLSLeonardo Noboru Seito
- Erika Marques da CunhaECErika Marques da Cunha
- Claudio C. FilgueirasCFClaudio C. Filgueiras
- Yael Abreu-VillaçaYAYael Abreu-Villaça
- Alex C. ManhãesAMAlex C. Manhães
- Clarissa Menezes Maya-MonteiroCMClarissa Menezes Maya-Monteiro
- Maria das Graças HenriquesMHMaria das Graças Henriques
- Thomas Eichenberg KraheTKThomas Eichenberg Krahe
Preprint
Abstract
Background: Glioblastoma is the most invasive and malignant brain tumor, for which no effective treatment is currently available. Heat shock protein 90 (HSP90) is a potential target for the treatment of different types of cancer. Herein, we investigated the effect of gedunin, an HSP90 inhibitor, in murine GL261 glioblastoma in vitro and in vivo models. Methods: Gedunin effects were assessed by in vitro cell viability assay (MTT), apoptosis (PI/Annexin staining), proliferation (CFSE), invasion (transmigration, scratch assay and zymography), protein detection (western blot) and in vivo orthotopic glioblastoma model (brain computed tomography and histology). Results: Gedunin treatment decreased GL261 cell proliferation and triggered apoptosis in a concentration-dependent manner. Gedunin also reduced GL261 cell migration and metalloproteinase-2 activity, suggesting that it impairs glioblastoma cell invasion. Despite the reduction of total protein content in gedunin-treated cells, the phosphorylation of STAT3 and ERK1/2 pathways was enhanced within 24 h. In situ treatment with gedunin did not significantly reduce tumor volume. Still, it reduced the tumor central area and the presence of vascular structures in xenograft glioblastoma in C57BL/6 mice, a clinical feature associated with morbidity and mortality. Conclusion: Gedunin inhibits murine glioblastoma cell growth and proliferation by inducing apoptosis. GraphicalKeywords
This publication has 95 references indexed in Scilit:
- Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancerBreast Cancer Research, 2012
- Toxicity after radiochemotherapy for glioblastoma using temozolomide - a retrospective evaluationRadiation Oncology, 2011
- Apoptosis and Beyond: Cytometry in Studies of Programmed Cell Death2011
- Increased expression of co-chaperone HOP with HSP90 and HSC70 and complex formation in human colonic carcinomaCell Stress and Chaperones, 2010
- Mechanistic Evaluation of the Novel HSP90 Inhibitor NVP-AUY922 in Adult and Pediatric GlioblastomaMolecular Cancer Therapeutics, 2010
- BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factorsBMC Cancer, 2010
- Gedunin, a Novel Hsp90 Inhibitor: Semisynthesis of Derivatives and Preliminary Structure−Activity RelationshipsJournal of Medicinal Chemistry, 2008
- Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced CancerClinical Cancer Research, 2007
- In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitroNature Protocols, 2007
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005